Work

POSTER: CT-278: Overall and Progression-Free Survival in Patients With Epstein-Barr Virus–Driven Posttransplant Lymphoproliferative Disease Following Tabelecleucel Treatment: Results From the Phase 3 ALLELE Trial

Year: 2026

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(26)01524-7

Authors: Sylvain Choquet, Armin Ghobadi, Sunita Nasta, Sridhar Chaganti, Sarah Nikiforow, Amer Beitinjaneh, Sonali Chaudhury, Rabi Hanna, Robert Baiocchi, Glen Lew, Ashley Swanson, Sandrine Roye, Daan Dierickx, Susan Prockop

Institutions: Pitié-Salpêtrière Hospital, Washington University in St. Louis, University of Pennsylvania, University Hospitals Birmingham NHS Foundation Trust, Dana-Farber Cancer Institute, University of Miami, Jackson Memorial Hospital, Lurie Children's Hospital, Cleveland Clinic, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Pierre Fabre (France), Universitair Ziekenhuis Leuven, Boston Children's Hospital, Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Language: English

Topic: Viral-associated cancers and disorders

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7204713708

FWCI:

Cites:

Cited by:

Related to: 10